J Clin Pharmacol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (2)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ma, J. D.
Right arrow Articles by Bertino, J. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ma, J. D.
Right arrow Articles by Bertino, J. S., Jr.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

METHODS

Limited Sampling Strategy of S-Warfarin Concentrations, but Not Warfarin S/R Ratios, Accurately Predicts S-Warfarin AUC during Baseline and Inhibition in CYP2C9 Extensive Metabolizers

Joseph D. Ma, PharmD, Anne N. Nafziger, MD, MHS, Angela D. M. Kashuba, PharmD, Myong-Jin Kim, PharmD, Andrea Gaedigk, PhD, Elizabeth Rowland, BS, Jooran S. Kim, PharmD and Joseph S. Bertino, Jr., PharmD, FCP

From the Clinical Pharmacology Research Center (Dr. Ma, Dr. Nafziger, Dr. J. S. Kim, Dr. Bertino), Department of Medicine (Dr. Nafziger, Dr. Bertino), and Department of Pharmacy Services (Dr. Bertino), Bassett Healthcare, Cooperstown, New York; School of Pharmacy, University of North Carolina, Chapel Hill (Dr. Kashuba, Ms. Rowland); Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, Maryland (Dr. M.-J. Kim); and the Division of Pediatric Clinical Pharmacology and Experimental Therapeutics, Children's Mercy Hospital and Clinics, Kansas City, Missouri (Dr. Gaedigk).

S-warfarin area under the concentration-time curve (AUC0-{infty}) and clearance are used as measures of cytochrome P450 (CYP) 2C9 activity. In addition, warfarin S/R ratios are used to assess CYP2C9 activity. The determination of S-warfarin AUC0-{infty} requires multiple blood samples. Limited sampling strategy (LSS) is a validated technique that estimates AUC0-{infty} using limited blood samples. The objective of this study was to evaluate LSS of S-warfarin concentrations and warfarin S/R ratios to predict S-warfarin AUC0-{infty} during CYP2C9 baseline activity and inhibition with fluvastatin. Fifty-one healthy subjects, genotyped as CYP2C9 extensive metabolizers, were administered oral warfarin 10 mg. Blood samples were collected over 96 hours. S-warfarin AUC0-{infty} equations were derived from a training set of 20 subjects using multiple linear regression. Validation of the equations used data from the remaining 31 subjects. All derived equations were within acceptable limits for measures of bias and precision. Single-point and two-point S-warfarin concentrations, but not warfarin S/R ratios, were predictive of S-warfarin AUC0-{infty} during CYP2C9 baseline activity and inhibition. No correlation was observed between CYP2C9*1/*1 and *1/*2 genotypes and either S-warfarin concentrations or warfarin S/R ratios. The equation using two-point S-warfarin concentrations at 24 and 48 hours was the most accurate predictor of S-warfarin AUC0-{infty}. LSS using S-warfarin concentrations is an efficient and accurate technique to evaluate S-warfarin AUC0-{infty} when using warfarin as a CYP2C9 probe drug.


Key Words: CYP2C9S-warfarinwarfarin S/R ratioslimited sampling strategydrug metabolism

Address for reprints: Joseph S. Bertino Jr., PharmD, FCP, Clinical Pharmacology Research Center, Bassett Healthcare, One Atwell Road, Cooperstown, NY 13326-1394.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
J Clin PharmacolHome page
L. S. Lee, J. S. Bertino Jr, and A. N. Nafziger
Limited Sampling Models for Oral Midazolam: Midazolam Plasma Concentrations, Not the Ratio of 1-Hydroxymidazolam to Midazolam Plasma Concentrations, Accurately Predicts AUC as a Biomarker of CYP3A Activity
J. Clin. Pharmacol., February 1, 2006; 46(2): 229 - 234.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 by the American College of Clinical Pharmacology